Search With Term
Recent Industry Update
- GSK’s disinvestment of Chiron Behring to Bharat Biotech
- FDA approved Cablivi (caplacizumab-yhdp) for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura
- Insight on EU’s safety features of unique identifier & anti-tampering device on outer packaging require for medicines
- Recordati received exclusive rights to commercialize Juxtapid in Japan from Aegerion Pharmaceuticals
- Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
- USFDA approved first generic of Advair Diskus
- USFDA accepted the Roche’s sBLA for Tecentriq (atezolizumab) in combination with Abraxane
- USFDA approved Imbruvica in combo with obinutuzumab for adult patients with previously untreated CLL/SLL
- Pfizer’s launches awareness and advocacy program on antibiotic resistance
- What is an “audit trail”?
- US FDA approval of 0.5 ml dose of Sanofi’s Fluzone Quadrivalent in children as young as 6 months of age
- Key Insights on 2018 USFDA new drug approval
- Abbott to acquire medical device company, Cephea Valve Technologies
- Sandoz introduces Symjepi 0.3 mg injection in US market to treat allergic reactions
- US FDA accepts Roche’s sBLA for Tecentriq in combo with Abraxane and carboplatin to treat metastatic NSCLC
- Aurobindo Pharma to acquire oncology products from Spectrum Pharmaceuticals in $300 mn
- Bristol-Myers Squibb to acquire Celgene in deal worth $74 billion
- Pfizer and GlaxoSmithKline to merge consumer healthcare units
- Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
- Boehringer Ingelheim’s ASF COMBAT market launch: East to use Tool in prevention of African swine fever
- 2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
- 2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
- US FDA approves Supernus’ sNDA to expand Oxtellar XR label
- Is it always New molecule is first approved in USFDA, instead of the EU approval?
- AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
- Novartis app for opium addicts gets US approval
- AMAG Pharmaceuticals to Acquire Perosphere and Its Anticoagulant
- Insight on USFDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor
- Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
- What is pediatric exclusivity?
Monthly Archieves
- February 2019 (5)
- January 2019 (12)
- December 2018 (10)
- November 2018 (19)
- October 2018 (7)
- September 2018 (4)
- August 2018 (14)
- July 2018 (34)
- June 2018 (2)
- May 2018 (14)
- April 2018 (8)
- March 2018 (7)
- February 2018 (6)
- January 2018 (6)
- December 2017 (9)
- November 2017 (9)
- October 2017 (14)
- September 2017 (12)
- August 2017 (12)
- July 2017 (11)
- June 2017 (12)
- May 2017 (18)
- April 2017 (11)
- March 2017 (20)
- February 2017 (15)
- January 2017 (12)
- December 2016 (23)
- November 2016 (20)
- October 2016 (7)
- September 2016 (15)
- August 2016 (21)
- July 2016 (36)
- June 2016 (20)
- May 2016 (24)
- April 2016 (21)
- March 2016 (27)
- February 2016 (24)
- January 2016 (19)
- December 2015 (8)
- November 2015 (16)
- October 2015 (25)
- September 2015 (22)
- August 2015 (12)
- July 2015 (32)
- June 2015 (33)
- May 2015 (32)
- April 2015 (19)
- March 2015 (10)
- February 2015 (17)
- January 2015 (33)
- December 2014 (41)
- November 2014 (20)
- October 2014 (10)
- September 2014 (10)